PSTX   $2.7199999999999998  -1.81% Market Closed After Close 2.72 0.00%

Poseida Therapeutics Inc
Last Events:

2023-08-09 Signal in Stochastic changed from bearish recovery to bearish weakening. The stochastic indicator is in the oversold territory and it heading north. These factors indicate that perhaps the downside trend is coming to an end. Last signal: main and signal line crossing.

2023-08-09 Signal in MACD changed from bearish recovery to bullish reversal. Oscillator MACD is in the negative territory it crossed the signal line from the bottom and grows. These factors mean that the market confirms the end of the downward trend. Last signal: main and signal line crossing.

2023-08-09 Signal in RSI changed from bearish recovery to bullish. RSI indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: entrance to the overbought zone.

2023-08-09 Signal in EMA20 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.

2023-08-05 Trend pattern changed from расширяющийся канал to канал.

2023-08-05 Signal in Stochastic changed from bullish reversal to bearish recovery. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: main and signal line crossing.

2023-08-04 Signal in MACD changed from bearish weakening to bearish recovery. Oscillator MACD is in the negative territory it's lower than the signal line and falls. These factors mean that negative mood prevails. Last signal: main and signal line crossing.

2023-08-03 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.


Current temperature: 0.00
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 3
Target Price Mean 14.00
Mean unverified/preliminary 14.00 / 14.00
Target Price Low / High 10.00 / 20.00
Median / STD DEV 12.00 / 5.29
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy ActivelyBuy Buy
rsi Sell ActivelyBuy None
macd None None None
stoch None None None
ma20 None ActivelyBuy Sell
ma50 None None None
ma100 Buy Buy ActivelyBuy
Candlestick PatternNov. 14, 2024 Bearish Three Outside Down - pattern is a made up of three candlesticks. A white candlestick appears on the first day in a uptrend. The second day body engulfs the white body of the first day. A black candlestick on the third day with a lower close than the second day. Considered to be a bearish reversal pattern.
ISIN US73730P1084
ceo Dr. Kristin Yarema Ph.D.
Website https://poseida.com
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.